Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First in Human Study of M4344 in Participants With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02278250
Recruitment Status : Completed
First Posted : October 29, 2014
Last Update Posted : November 2, 2021
Sponsor:
Collaborator:
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
EMD Serono ( EMD Serono Research & Development Institute, Inc. )

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily dose schedule in participants with advanced solid tumors. This investigation is a three part study examining M4344 alone and in combination with carboplatin to determine the safety and maximum tolerated dose.

Condition or disease Intervention/treatment Phase
Solid Tumor Advanced Solid Tumor Drug: M4344 Drug: Carboplatin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 98 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Actual Study Start Date : January 26, 2015
Actual Primary Completion Date : June 16, 2021
Actual Study Completion Date : September 24, 2021

Arm Intervention/treatment
Experimental: Part A: M4344 BIW
Dose escalation of M4344 administered BIW as a single agent.
Drug: M4344
Dose escalation of M4344 administered as a single agent.
Other Name: VX-803

Experimental: Part A2: M4344 BID or once daily
Dose escalation of M4344 administered BID or once daily as a single agent.
Drug: M4344
Dose escalation of M4344 administered as a single agent.
Other Name: VX-803

Experimental: Part A3: M4344 Drug holiday schedule
Dose escalation of M4344 administered in a drug holiday schedule (different schedule with either 3 days once daily (QD) or BID followed by 4 days of pausing, 5 days of QD or BID followed by 2 days of pausing, 7 days of QD or BID dosing followed by 7 days of pausing or 14 days of QD or BID dosing followed by 7 days of pausing may be explored. Other dosing holiday schedules may be explored if agreed by the sponsor and Investigators).
Drug: M4344
Dose escalation of M4344 administered in a drug holiday schedule (different schedule with either 3 days once daily (QD) or BID followed by 4 days of pausing, 5 days of QD or BID followed by 2 days of pausing, 7 days of QD or BID dosing followed by 7 days of pausing or 14 days of QD or BID dosing followed by 7 days of pausing may be explored. Other dosing holiday schedules may be explored if agreed by the sponsor and Investigators) applies to A3.
Other Name: VX-803

Experimental: Part B1: M4344 + Carboplatin
Dose escalation of M4344 in combination with carboplatin.
Drug: M4344
Dose escalation of M4344 administered as a single agent.
Other Name: VX-803

Drug: Carboplatin
Carboplatin will be administered in combination with escalated dose of M4344.

Experimental: Part C1: M4344 BID or once daily
An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ARID1A.
Drug: M4344
Dose escalation of M4344 administered as a single agent.
Other Name: VX-803

Experimental: Part C2: M4344 BID or once daily
An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the genes ATRX and/or DAXX.
Drug: M4344
Dose escalation of M4344 administered as a single agent.
Other Name: VX-803

Experimental: Part C3: M4344 BID or once daily
An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ataxia telangiectasia mutated (ATM).
Drug: M4344
Dose escalation of M4344 administered as a single agent.
Other Name: VX-803

Experimental: Part C4: M4344 Drug holiday schedule
An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ARID1A.
Drug: M4344
M4344 at the Recommended Phase 2 dose (RP2D) from Part A3 in expansion cohorts.
Other Name: VX-803

Experimental: Part C5: M4344 Drug holiday schedule
An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the genes ATRX and/or DAXX.
Drug: M4344
M4344 at the Recommended Phase 2 dose (RP2D) from Part A3 in expansion cohorts.
Other Name: VX-803

Experimental: Part C6: M4344 Drug holiday schedule
An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ataxia telangiectasia mutated (ATM).
Drug: M4344
M4344 at the Recommended Phase 2 dose (RP2D) from Part A3 in expansion cohorts.
Other Name: VX-803




Primary Outcome Measures :
  1. Parts A, A2, A3, B1, C1, C2, C3, C4, C5 and C6: Number of Participants with Treatment Emergent Adverse Events and Serious Adverse Events [ Time Frame: Part A, A2, A3, B1: From baseline until 14 days after discontinuation of study treatment (assessed up to approximately 6 years); Part C1, C2, C3, C4, C5, C6: up to 30 days after discontinuation of study treatment (assessed up to approximately 6 years) ]
  2. Parts A, A2, A3, B1, C1, C2, C3, C4, C5 and C6: Number of Participants with Clinically Significant Changes in Clinical Laboratory Values (Serum Chemistry and Hematology), Vital Signs, and Electrocardiogram (ECG) Assessments [ Time Frame: Part A, A2, A3, B1: From baseline until 14 days after discontinuation of study treatment (assessed up to approximately 6 years); Part C1, C2, C3, C4, C5, C6: up to 30 days after discontinuation of study treatment (assessed up to approximately 6 years) ]
    Number of participants with clinically significant changes in clinical laboratory values (serum chemistry and hematology), vital signs, and ECG assessments were assessed.

  3. Part A, A2 and A3: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 (RP2D) of Single-Agent M4344 Administered BIW or BID or Once Daily or Drug Holiday Schedule [ Time Frame: Evaluation for dose-limiting toxicity will be during Cycle 1 (each cycle is of 21 days) for each participant ]
  4. Part B1: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 (RP2D) of M4344 Administered in Combination with Carboplatin [ Time Frame: Evaluation for dose-limiting toxicity will be during Cycle 1 (each cycle is of 21 days) for each participant ]
  5. Part C1, C2, C3, C4, C5 and C6: Proportion of Participants With Objective Response according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Assessed by the Investigator [ Time Frame: Baseline until disease progression or start of new anti-cancer treatment line (approximately up to 6 years) ]

Secondary Outcome Measures :
  1. Part A: Area Under the Concentration Curve (AUC) of M4344 [ Time Frame: Cycle 1, Day 1 up to Cycle 1, Day 15 (each cycle is of 21 days) ]
  2. Part A: Maximum Observed Plasma Concentration (Cmax) of M4344 [ Time Frame: Cycle 1, Day 1 up to Cycle 1, Day 15 (each cycle is of 21 days) ]
  3. Part A: Time to Reach Maximum Plasma Concentration (tmax) of M4344 [ Time Frame: Cycle 1, Day 1 up to Cycle 1, Day 15 (each cycle is of 21 days) ]
  4. Part A2 and A3: Area Under the Concentration Curve (AUC) of M4344 and Metabolites [ Time Frame: Cycle 1, Day 1 up to Cycle 1, Day 15 (each cycle is of 21 days) ]
  5. Part A2 and A3: Maximum Observed Plasma Concentration (Cmax) of M4344 and Metabolites [ Time Frame: Cycle 1, Day 1 up to Cycle 1, Day 15 (each cycle is of 21 days) ]
  6. Part A2 and A3: Time to Reach Maximum Plasma Concentration (tmax) of M4344 and Metabolites [ Time Frame: Cycle 1, Day 1 up to Cycle 1, Day 15 (each cycle is of 21 days) ]
  7. Parts A, A2, A3 and B1: Objective Tumor Response (OR) and Disease Stabilization (SD) as Evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [ Time Frame: Every 2 Cycles (each cycle is of 21 days) until tumor progression (approximately up to 6 years) ]
  8. Part B1: Area Under the Concentration Curve (AUC) of M4344 [ Time Frame: Cycle 1, Day 2 up to Cycle 1, Day 9 (each cycle is of 21 days) ]
  9. Part B1: Maximum Observed Plasma Concentration (Cmax) of M4344 [ Time Frame: Cycle 1, Day 2 up to Cycle 1, Day 9 (each cycle is of 21 days) ]
  10. Part B1: Time to Reach Maximum Plasma Concentration (tmax) of M4344 [ Time Frame: Cycle 1, Day 2 up to Cycle 1, Day 9 (each cycle is of 21 days) ]
  11. Part C1, C2, C3, C4, C5 and C6: Confirmed Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Assessed by Investigator [ Time Frame: Baseline, until disease progression or start of new anti-cancer treatment line (approximately up to 6 years) ]
  12. Part C1, C2, C3, C4, C5 and C6: Duration of Response Assessed From Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 [ Time Frame: Baseline until PD, death, or last adequate tumor assessment (approximately up to 6 years) ]
  13. Part C1, C2, C3, C4, C5 and C6: Progression Free Survival (PFS) as Evaluated by RECIST Version 1.1 [ Time Frame: Baseline until tumor progression (approximately up to 6 years) ]
  14. Part C1, C2, C3, C4, C5 and C6: Overall Survival (OS) [ Time Frame: Assessed every 3 months for up to 1 year or more or until study closure, whichever comes first (approximately up to 6 years) ]
  15. Part C1, C2, C3, C4, C5 and C6: Area Under the Concentration Curve (AUC) of M4344 and Metabolites [ Time Frame: Cycle 1, Day 1 up to Cycle 12, Day 1 (each cycle is of 21 days) ]
  16. Part C1, C2, C3, C4, C5 and C6: Maximum Observed Plasma Concentration (Cmax) of M4344 and Metabolites [ Time Frame: Cycle 1, Day 1 up to Cycle 12, Day 1 (each cycle is of 21 days) ]
  17. Part C1, C2, C3, C4, C5 and C6: Time to Reach Maximum Plasma Concentration (tmax) of M4344 and Metabolites [ Time Frame: Cycle 1, Day 1 up to Cycle 12, Day 1 (each cycle is of 21 days) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Part A, A2 and A3: Participants with one histologically or cytologically confirmed malignant advanced solid tumor, for which no standard therapy is available which may convey clinical benefit
  • Part B1: Participants with one histologically or cytologically confirmed malignant advanced solid tumor, for which no standard therapy is available which may convey clinical benefit and/or participants must have progressed after at least 1 prior chemotherapy regimen in the metastatic setting, and for which carboplatin would be considered standard of care.
  • Part C: Participants with 1 histologically or cytologically confirmed malignant advanced solid tumors for which no recommended standard therapy is available (that is, participants who have exhausted all standard of care options according to National Comprehensive Cancer Network [NCCN] Guidance) which may convey clinical benefit, and whose tumor has at least 1 of the following biomarkers as determined by a central trial assay or by an assay with appropriate regulatory status: - C1 or C4: loss-of-function mutations in the gene ARID1A - C2 or C5: loss-of-function mutations in the genes ATRX and/or DAXX - C3 or C6: loss-of-function mutation in the gene ataxia telangiectasia mutated (ATM) - This mandatory biomarker assessment must be conducted during screening on a fresh tumor biopsy (or a biopsy obtained after the end of the previous treatment regimen). If this is not possible for medical reason(s), available archival tumor material can be used (historical data should not be used to confirm biomarker status)
  • Measurable disease either according to RECIST criteria (Version 1.1)
  • WHO performance status of 0 or 1
  • Life expectancy of greater than or equal to (>=)12 weeks
  • Hematological and biochemical indices within acceptable ranges at Screening
  • Other protocol defined inclusion criteria could apply

Exclusion Criteria:

  • Radiotherapy, unless brief course for palliative therapy, endocrine therapy, target-specific therapy, immunotherapy, or chemotherapy during the 4 weeks (6 weeks for nitrosoureas and Mitomycin-C, and 4 weeks for investigational medicinal products) or 4 drug half-lives before first dose of study drug, whichever is greater
  • Part B1: More than 6 cycles of prior therapy with carboplatin
  • Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the investigator should not exclude the participant
  • Part B1: Any known history of Grade 4 thrombocytopenia with any prior chemotherapy regimen
  • Brain metastases unless asymptomatic, treated, stable, and not requiring steroids for at least 4 weeks before first dose of study drug
  • Female participants who are already pregnant or lactating, or plan to become pregnant within 6 months of the last dose of study drug are excluded. Female participants of childbearing potential must adhere to contraception guidelines. Female participants will be considered to be of nonchildbearing potential if they have undergone surgical hysterectomy or bilateral oophorectomy or have been amenorrheic for over 2 years with a screening serum follicle-stimulating hormone (FSH) level within the laboratory's reference range for postmenopausal females.
  • Male participants with partners of childbearing potential must agree to adhere to contraception guidelines. Men with pregnant or lactating partners or partners who plan to become pregnant during the study or within 6 months of the last dose of study drug are excluded.
  • Major surgery less than or equal to (<=) 4 weeks before first dose of study drug or incomplete recovery from a prior major surgical procedure
  • Serious co-morbid medical conditions, including clinically-significant cardiac disease
  • Other protocol defined exclusion criteria could apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02278250


Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109-5901
United States, Missouri
Washington University in St. Louis
Saint Louis, Missouri, United States, 63110
United States, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 8903
United States, New York
Memorial Sloan-Kettering Cancer Center (MSKCC)
New York, New York, United States, 10065
United States, Tennessee
Tennessee Oncology
Nashville, Tennessee, United States, 37203
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Wisconsin
Froedtert & The Medical College of Wisconsin
Wauwatosa, Wisconsin, United States, 53226
Netherlands
Erasmus Medisch Centrum
Rotterdam, Netherlands, 3075 EA
Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
"Fundacion Jimenez Diaz START Madrid. Oncology Phase I"
Madrid, Spain
START Madrid. Fundacion Jimenez Diaz- Oncologia-Fase I
Madrid, Spain
"Hospital Clinico Universitario de Valencia Servicio de Hematologia y Oncologia Medica"
Valencia, Spain
United Kingdom
Sarah Cannon Research Institute UK
London, Greater London, United Kingdom, W1G 6AD
Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Sponsors and Collaborators
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany
Investigators
Layout table for investigator information
Study Director: Medical Responsible EMD Serono Research & Development Institute, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: EMD Serono Research & Development Institute, Inc.
ClinicalTrials.gov Identifier: NCT02278250    
Other Study ID Numbers: MS201922-0001
VX14-803-001 ( Other Identifier: Other )
2014-003838-86 ( EudraCT Number )
First Posted: October 29, 2014    Key Record Dates
Last Update Posted: November 2, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Keywords provided by EMD Serono ( EMD Serono Research & Development Institute, Inc. ):
VX14-803-001
VX-803
M4344
Advanced Solid Tumor
Cytotoxic Chemotherapy
Carboplatin
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Carboplatin
Antineoplastic Agents